No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MESO Mesoblast
- 7.230
- +0.130+1.83%
Close Jul 19 16:00 ET
- 7.340
- +0.110+1.52%
Pre 08:15 ET
825.12MMarket Cap-8329P/E (TTM)
7.500High7.040Low387.18KVolume7.320Open7.100Pre Close2.83MTurnover0.85%Turnover RatioLossP/E (Static)114.12MShares8.66052wk High1.62P/B331.29MFloat Cap1.61052wk Low--Dividend TTM45.82MShs Float106.340Historical High--Div YieldTTM6.48%Amplitude1.610Historical Low7.297Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Reported Sunday, Mesoblast Begins Enrollment In Phase 3 Trial Of Rexlemestrocel-L For Chronic Low Back Pain
Up 308% in 6 Months, Why Is the Mesoblast Share Price Tumbling Today?
Shares in the S&P/ASX 300 Index (ASX: XKO) biotech company closed on Friday trading for $1.15. In morning trade on Monday, they are changing hands for $1.135 apiece, down 1.3%.
Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain
FDA has designated rexlemestrocel-L a Regenerative Medicine Advanced Therapy (RMAT) for the treatment of chronic low back pain.
Mesoblast Launches Phase 3 Trial for Back Pain
Mesoblast Limited (MEOBF) Was Downgraded to a Hold Rating at Jefferies
Mesoblast Director's Holdings Surge Post-AGM
Comments
$Mesoblast(MESO.US$ Mesoblast (MESO) has released an update. Mesoblast Limited has resubmitted a Biologics License Application (BLA) to the FDA for Ryoncil®, aiming to treat children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD). The resubmission, buoyed by promising Phase 3 study results demonstrating significant survival benefits, could meet an urgent need for effective treatment in this patient group, as current survival outcomes are poor and no FDA-approved treatm...
2
$Mesoblast(MESO.US$ which is developing off-the-shelf cellular medicines for life-threatening inflammatory conditions, is planning to file a Biologics License Application for Ryoncil with the FDA next week.
1
2
$Mesoblast(MESO.US$ .write time to sell !! drop since form monday
$Mesoblast(MESO.US$ ..Even drop no one willing to sell!!!!
1
$Mesoblast(MESO.US$ my cards never lie! But looking at the head guy for yhis company and all his achievements it was a no brainer! Had no doubts here! Hope that guy stayed in!
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
101674396 : Hold or sell?
TrytosaveabitOP 101674396: Sorry I don’t give buy/sell advice! There’s no way for me to know others risk tolerance or the type of trade they are doing! I will say that I am still bullish on this! NFA JMO! GL